Glenmark sees 4-6 product approvals from USFDA in FY16

The company's diabetes portfolio contributes ~INR. 100 crore to the total annual revenue and has been growing at 20% per annum.

Glenmark Pharmaceuticals Ltd. is expecting approval for 4-6 new products from the US Food & Drug Administration (USFDA) during the second half of the current financial year.

The company has received eight product approvals from the US regulator in the last six months, President and Head of India Business, Sujesh Vasudevan and Vice President – Corporate Strategy, Jason D’souza said at a press in Hyderabad on Monday.

The expected new launches this year in the US could be 12-14.

In the domestic market, Glenmark expects the growth to be 18-20% this year, which will be driven by Teneligliptin brands Zita Plus and Ziten.

The company's diabetes portfolio contributes ~INR. 100 crore to the total annual revenue and has been growing at 20% per annum.

Glenmark plans to launch a Teneliglptin combination diabetes generic drug in the domestic market once the phase-III clinical trials are over, Vasudevan said.